Companion Dog Syndicate content

Jan 14, 2020

Crisdesalazine demonstrated significant improvement in cognition function in the primary outcome measure
Crisdesalazine demonstrated significant improvement in dementia in the secondary outcome measures

YONGIN, South Korea--(BUSINESS WIRE)--GNT Pharma has successfully completed a Phase III clinical...